Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers.

ABSTRACT:

Background

Localized prostate cancer (PCa) is a largely heterogeneous disease regarding its clinical behavior. Current risk stratification relies on clinicopathological parameters and distinguishing between indolent and aggressive cases remains challenging. To improve risk stratification, we aimed to identify new prognostic markers for PCa.

Methods

We performed an in silico analysis on publicly available PCa transcriptome datasets. The top 20 prognostic genes were assessed in PCa tissue samples of our institutional cohort (n = 92) using the NanoString nCounter technology. The three most promising candidates were further assessed by immunohistochemistry (IHC) in an institutional (n = 121) and an independent validation cohort from the EMPACT consortium (n = 199). Cancer-specif

SUBMITTER: Olah C 

PROVIDER: S-EPMC12399428 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature